ImaginAb completes licensing agreement with UCLA

ImaginAb and the University of California, Los Angeles (UCLA) have concluded a technology licensing agreement relating to novel fluorine chemistry for the rapid and robust labeling of proteins, peptides and biomolecules for diagnostic imaging with PET.

The licensed technology originates from the UCLA's Crump Institute for Molecular Imaging through research sponsored by the U.S. Department of Energy. The agreement grants exclusivity to ImaginAb for antibodies and antibody fragments, according to the Inglewood, Calif.-based company.

Around the web

To fully leverage today's radiology IT systems, standardization is a necessity. Steve Rankin, chief strategy officer for Enlitic, explains how artificial intelligence can help.

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.